Biocracked
Longevity Metabolism Peptides Research Supplements Trending: supplements clinical trial longevity nad+ nootropics
Approach: conceptual metaphor. Palette: bold color field (D). A single glass eyedropper hangs just above a shallow, clear glass dish, and one golden oil droplet is caught mid-fall. Directly beneath it, a ripple spreads across the surface. The droplet stands for a small, single dose of OEA, and the widening ripple stands for the gut's natural hormone response spreading outward. The backdrop is a seamless saturated tomato-red field. The camera sits at a low three-quarter angle, with shallow depth of field and a crisp, frozen-motion macro focus on the droplet. Hard but clean studio light from the upper left gives the droplet a bright specular highlight and casts a soft, warm-red shadow. A thin electric green (#00e676) reflection runs along the rim of the dish as a subtle accent. The mood is precise, cautious and quietly curious. There is no text.
Metabolism

A 'Natural GLP-1 Booster'? 300 mg OEA Raised GLP-1 Up to 25% in 15 Minutes

Nova Chen · · 4 min read

The Natural GLP-1 Booster? What a New Crossover Trial Actually Found

Your gut already makes its own GLP-1, the hormone that GLP-1 drugs imitate. A new trial suggests a single dose of an oleoylethanolamide (OEA) supplement called TRPTI™ can nudge that natural output upward within minutes of swallowing it. The headline number is a 20-25% increase over placebo at key timepoints. That is real, but it is not Ozempic, and the details matter.

The Quick Facts

  • Journal: Frontiers in Endocrinology (2026), registered as NCT06840080
  • Design: fixed-sequence, single-blind, placebo-controlled, three-period crossover
  • Participants: 37 adults with a BMI of 25-34.9 kg/m²
  • Doses: one-time placebo, 150 mg TRPTI™, or 300 mg TRPTI™ after an overnight fast
  • Monitoring: blood sampled over 8 hours, with standardised meals at 15 minutes and 4 hours after dosing
  • Measured: GLP-1, GIP, DPP-4, insulin, glucose and glucagon

What Is OEA, and Why Does It Matter?

Oleoylethanolamide is a lipid your body makes in the small intestine. It is involved in nutrient sensing and gut-derived hormonal signalling, essentially part of the conversation between your gut and your appetite. TRPTI™ is a bioavailable formulation of OEA, designed to support metabolic and appetite-related pathways.

Because OEA is an endogenous compound, "natural" is a fair description of the molecule. It doesn't tell you how well a supplement version works, which is what this trial set out to test.

The Big Finding: Incretins Rose Quickly

The 300 mg dose produced the largest incretin responses. Compared with placebo, it was significantly greater during selected pre-specified post-dosing and post-meal periods, with elevations detectable within 15 minutes of ingestion. At key timepoints, GLP-1 concentrations ran roughly 20-25% above placebo. GIP, the other major incretin, showed similar significant increases.

Two other findings stood out:

  • DPP-4 shifted. DPP-4 is the enzyme that breaks down incretins. Significant concentration changes appeared at later timepoints, which the authors describe as a potential association with serum DPP-4 modulation. This is a signal, not a mechanism proven.
  • Meals got smaller. Participants consumed significantly less at meals in both TRPTI™ groups. The abstract reports statistical significance but no magnitude, so don't read it as a specific calorie cut.

Safety biomarkers stayed within normal ranges at both doses, and the authors describe acute tolerability as good.

Why This Isn't Ozempic

The "natural GLP-1 booster" framing is catchy, but a careful comparison matters.

Drugs like semaglutide are GLP-1 receptor agonists. They activate the receptor directly and continuously, and they are tested in long trials, with outcomes such as sustained weight loss. TRPTI™ works differently. It appears to amplify your own post-meal hormone release, and the trial measured that for about 8 hours after a single dose.

A 20-25% rise in a circulating hormone is a modest, physiological nudge. It is not equivalent to the pharmacological receptor activation of a prescription drug, and this study makes no weight-loss claim. It measured hormones, blood markers and meal intake, not body weight. Anyone suggesting this is a drug alternative is going beyond the data.

The Caveats You Should Know

  1. It was acute. Participants took one dose. We don't know what happens with daily use over weeks or months, whether the effect persists, or whether the body adapts.
  2. Industry funding. The study sponsor was Gencor Pacific, and one author is a Gencor employee. The other authors declared no conflicts. That doesn't invalidate the findings, but it calls for independent replication.
  3. Single-blind and fixed-sequence. Participants didn't know what they were taking, but the researchers did. All participants also went through the treatments in a set order rather than a randomised one, so order or period effects can't be fully ruled out.
  4. Small, specific sample. There were 37 adults who were overweight or had class I obesity. The trial didn't test people with diabetes, older adults or people already on metabolic medications.
  5. Surrogate outcomes. Higher hormone levels and smaller meals are encouraging, but they are not proof of lasting weight loss or better health outcomes.

What This Means for You

Dose studied: 300 mg of TRPTI™ produced the strongest effects. The 150 mg dose was also tested, but 300 mg gave the largest incretin responses, so that is the evidence-backed dose.

Timing: In the trial, participants were dosed fasted, and a standardised meal followed 15 minutes later, with a second at 4 hours. The practical reading is to take it shortly before a meal, as studied. The research doesn't establish whether other timings work as well.

Who it may be for: Generally healthy adults with a BMI in the overweight to class I obesity range (25-34.9) who are curious about nutritional approaches to appetite and metabolic health. This is the population studied, and it is still early evidence.

  • People taking GLP-1 medications, DPP-4 inhibitors or other diabetes drugs, since this research doesn't address combining them (the DPP-4 finding makes that question relevant)
  • People with diabetes or other metabolic conditions, who weren't studied
  • Anyone pregnant or breastfeeding, or with a medical condition, since safety beyond a single dose in healthy adults is unknown
  • Anyone hoping for prescription-level weight loss. The evidence doesn't support that expectation.

The Bottom Line

TRPTI™ is an interesting entry in the effort to support the gut's own signalling. In this crossover trial, a single 300 mg dose raised GLP-1 and GIP responses by a meaningful but moderate margin, acted within 15 minutes, and coincided with reduced meal intake. It also looked acutely safe. The result is promising and preliminary. The next step is longer, larger, independently run trials that show whether these hormonal blips translate into lasting benefits.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

Share XFacebookLinkedInRedditWhatsApp
NC

Written by

Nova Chen

Nova Chen writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach: Macro science. Palette: B, warm. Extreme macro photograph of a clear glass vial of blood plasma held in a gloved hand, shot at a slight low angle so the camera looks up through the tube. The plasma is cloudy and creamy at the top, where large fat-rich particles gather, and it clears to translucent golden amber toward the bottom, showing the drop in triglyceride particles. Tiny suspended droplets catch the light as bright specks. Warm honey-colored backlight from a low window-like source glows through the liquid and casts copper highlights across the glass. The background is a soft blur of warm brown and amber, with a faint electric green reflection on the rim of the vial cap. The mood is calm, precise and cautious, with a shallow depth of field and a real clinical texture on the glass. No text or labels.
metabolism

Retatrutide Cut Large Triglyceride Particles 84%—But Read This First

BY DR. SYNAPSE ·

Retatrutide is best known for weight loss, but a new post hoc analysis of two phase 2 trials looked at what it did to the blood. Large triglyceride-rich lipoprotein particles fell by up to 84.4% in adults with type 2 diabetes, and ApoB dropped by roughly 21–24%. In the trial without diabetes, hsCRP fell 54.8% and IL-6 fell 29.6%, but those changes were not significant in the diabetes trial. The abstract reports no Lp(a) results and no per-dose breakdown. This is an unapproved prescription-class drug, not a supplement, and these are biomarkers, not proof of fewer heart attacks.
Approach: Macro science. Palette: B, warm. Extreme macro photograph of raw berberine: a small heap of vivid yellow-orange crystalline powder with needle-like crystal clusters, shot at a low 30-degree angle with a shallow depth of field. Beside it, a dry sliver of Berberis root bark shows its bright yellow inner wood and fibrous grain. The surface is a smooth dark walnut board. Low golden-hour side light from the left makes the crystals glint like amber glass and throws long warm copper shadows across the wood. One tiny electric green highlight reflects off a glass spatula edge in the soft background blur. The mood is quiet and investigative, with rich saturated honey and burnt-orange tones and no blue cast. Photorealistic, microscopy-like texture, no text or labels.
metabolism

Berberine vs. Metformin: The Pilot Trial Behind HbA1c 9.5% to 7.5%

BY HELIX WARD ·

A small 2008 pilot trial put berberine head-to-head with metformin in newly diagnosed type 2 diabetes, and the glucose-lowering effect looked similar. In the berberine group, HbA1c fell from 9.5% to 7.5% in three months. A second trial in 48 people already on treatment saw HbA1c drop from 8.1% to 7.3% and HOMA-IR fall 44.7%. But these were small studies in people with diabetes, and about a third of participants had GI side effects. Here is what the data show, what they don't, and what to know before you think about berberine.
Approach: Macro science. Palette: D, bold color field. Extreme close-up microscopy-style photograph of a dense cluster of oval, rod-shaped bacterial cells, rendered as slightly wrinkled, matte, pale cream-white forms with visible surface texture. They rest on a smooth, saturated magenta-pink gel surface. Several cells in the foreground are crisp, while the rest fall into soft shallow depth of field. One cell near the center is split open and visibly hollow, to suggest a dead, heat-treated organism. Camera is a low three-quarter angle, as if through a scanning microscope. Lighting is a single hard, warm-white side light that casts short crisp shadows and creates bright rim highlights. A thin electric green (#00e676) line of reflected light traces the edge of one cell. The mood is stark, curious and quietly skeptical. There is no text and no labels.
metabolism

The Gut Bacterium That Worked Better Dead: Akkermansia's 29% Edge

BY HELIX WARD ·

In the first human trial of Akkermansia muciniphila, the pasteurized (heat-killed) version, not the live one, produced the headline results. Insulin sensitivity rose 28.62% and fasting insulin fell 34.08% versus placebo in overweight, insulin-resistant adults. The weight and fat changes everyone hopes for did not reach statistical significance, and several authors hold patents and co-founded a company selling the bacterium. Here is what the study found, what it can't tell you, and what to check before buying a supplement.
A softly lit editorial still life on a pale oat-colored linen surface, shot from a slightly elevated three-quarter angle in a wide landscape frame. At center-left, a small matte white ceramic dish holds a modest pile of fine off-white powder, with a tiny brushed-brass measuring spoon resting beside it. Next to the dish stands a minimalist amber glass supplement bottle with a plain cream label and no readable text. A few capsules spill casually across the linen, some translucent and some opaque ivory. On the right side of the composition, a ripe blood orange cut in half and a handful of raw almonds sit on a light ash-wood board. A sprig of fresh rosemary adds a muted green accent. A sheer glass of water catches the light and throws a soft, rippled caustic pattern across the fabric. In the background, out of focus, a woman's hand in a soft sage-green knit sleeve rests near a ceramic mug. This suggests a calm morning routine without showing a face. Behind her, a tall window casts diffused, golden-hour light from the upper left, with gentle shadows and a creamy, shallow depth of field. The palette is warm and restrained: oat, ivory, terracotta, sage, and amber, with a single pop of coral from the blood orange. A thin, abstract line of muted terracotta paint, like a brushed arc, sweeps across the upper right background. It subtly evokes a rising curve without becoming a literal chart. The mood is calm, trustworthy, and contemporary, like a premium wellness and science journal feature. The image has crisp focus on the powder and bottle, natural film-like grain, soft contrast, and generous negative space in the upper third for headline overlay. It looks like a high-end editorial photograph with no text, logos, or futuristic elements.
metabolism

NMN's First Human Win: 250 mg a Day Lifted Muscle Insulin Sensitivity by About 25% in Prediabetic Women

BY DR. SYNAPSE ·

NMN has long been a darling of the longevity market, but human evidence was thin until a 2021 Washington University trial published in Science. In postmenopausal women with prediabetes who were overweight or obese, 250 mg of NMN daily for 10 weeks improved muscle insulin sensitivity by roughly 25%. Muscle insulin signaling and genes tied to muscle remodeling also improved, while the placebo group saw no change. But the benefit was narrow, and the study did not show NMN lowering blood sugar or reversing prediabetes. Here's what the trial found, who it applies to, and what it didn't change.

This page is available in

English العربيةবাংলাČeštinaDeutschEspañolفارسیFrançaisHausaहिन्दीHrvatskiBahasa IndonesiaItaliano日本語Basa Jawa한국어NederlandsਪੰਜਾਬੀPolskiPortuguêsRomânăРусскийSrpskiTürkçeУкраїнськаTiếng Việt中文